A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
Identifieur interne : 000301 ( PascalFrancis/Checkpoint ); précédent : 000300; suivant : 000302A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
Auteurs : Kai Schulze [Allemagne] ; Caroline Staib [Allemagne] ; Hermann M. Sch Tzl [Allemagne] ; Thomas Ebensen [Allemagne] ; Volker Erfle [Allemagne] ; Carlos A. Guzman [Allemagne]Source :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccination, Vaccin.
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0039741Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title>
<author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0039741</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 09-0039741 INIST</idno>
<idno type="RBID">Pascal:09-0039741</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000239</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000749</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000301</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000301</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</title>
<author><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>Technical University Munich</wicri:noRegion>
<wicri:noRegion>Institute for Virology, Technical University Munich</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>German Center for Environmental Health</wicri:noRegion>
<wicri:noRegion>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>Inhoffenstrasse 7</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Immune response</term>
<term>Immunization</term>
<term>Immunological adjuvant</term>
<term>Mucosa</term>
<term>Nucleocapsid</term>
<term>Protein</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Vaccinia virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus syndrome respiratoire aigu sévère</term>
<term>Virus vaccine</term>
<term>Vaccination</term>
<term>Réponse immune</term>
<term>Nucléocapside</term>
<term>Protéine</term>
<term>Adjuvant immunologique</term>
<term>Muqueuse</term>
<term>Immunisation</term>
<term>Vaccin</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccination</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>51</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SCHULZE (Kai)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STAIB (Caroline)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SCHÄTZL (Hermann M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>EBENSEN (Thomas)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ERFLE (Volker)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GUZMAN (Carlos A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7</s1>
<s2>38124 Braunschweig</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Virology, Technical University Munich</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical Cooperation Group "Antigen-Specific Immunotherapy", Helmholtz Zentrum München, German Center for Environmental Health</s1>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>6678-6684</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000196098830250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0039741</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus vaccine</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccinia virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vaccinia virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccination</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacunación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Réponse immune</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Immune response</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Respuesta inmune</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Nucléocapside</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nucleocapsid</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Nucleocápside</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Protéine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Protein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Proteína</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Adjuvant immunologique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Immunological adjuvant</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Coadyuvante inmunológico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Muqueuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Mucosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Mucosa</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunisation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunization</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunización</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Orthopoxvirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Chordopoxvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Poxviridae</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>026</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Schulze, Kai" sort="Schulze, Kai" uniqKey="Schulze K" first="Kai" last="Schulze">Kai Schulze</name>
</noRegion>
<name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A." last="Guzman">Carlos A. Guzman</name>
<name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M." last="Sch Tzl">Hermann M. Sch Tzl</name>
<name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
<name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000301 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000301 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:09-0039741 |texte= A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |